B-intervention	0	9	Tamoxifen
I-intervention	10	15	alone
O	16	22	versus
B-control	23	31	adjuvant
I-control	32	41	tamoxifen
O	42	45	for
B-eligibility	46	54	operable
I-eligibility	55	61	breast
I-eligibility	62	68	cancer
I-eligibility	69	71	of
I-eligibility	72	75	the
I-eligibility	76	83	elderly
O	83	84	:
O	85	89	long
O	89	90	-
O	90	94	term
O	95	102	results
O	103	105	of
O	106	109	the
O	110	115	phase
O	116	119	III
O	120	130	randomized
O	131	141	controlled
O	142	153	multicenter
O	154	159	GRETA
O	160	165	trial
O	165	166	.

O	167	169	To
O	170	178	evaluate
O	179	182	the
O	183	191	efficacy
O	192	194	of
O	195	204	tamoxifen
O	205	207	as
O	208	215	primary
O	216	225	treatment
O	226	228	in
O	229	234	women
O	235	239	aged
O	240	244	over
B-age	245	247	70
I-age	248	253	years
O	254	258	with
O	259	267	operable
O	268	274	breast
O	275	281	cancer
O	282	288	versus
O	289	296	surgery
O	297	305	followed
O	306	308	by
O	309	317	adjuvant
O	318	327	tamoxifen
O	327	328	.

O	329	337	Patients
O	338	346	randomly
O	347	355	received
O	356	365	tamoxifen
O	366	371	alone
O	372	373	(
O	373	376	160
O	377	379	mg
O	380	383	day
O	384	385	1
O	385	386	,
O	387	391	then
O	392	394	20
O	395	397	mg
O	397	398	/
O	398	401	day
O	401	402	)
O	403	406	for
O	407	408	5
O	409	414	years
O	415	417	or
O	418	425	surgery
O	426	434	followed
O	435	437	by
O	438	447	tamoxifen
O	448	449	(
O	449	451	20
O	452	454	mg
O	454	455	/
O	455	458	day
O	458	459	)
O	460	463	for
O	464	465	5
O	466	471	years
O	471	472	.

B-outcome-Measure	473	480	Overall
I-outcome-Measure	481	489	survival
O	490	493	was
O	494	497	the
O	498	502	main
O	503	508	study
O	509	512	end
O	513	518	point
O	518	519	;
O	520	529	secondary
O	530	540	objectives
O	541	549	included
B-outcome-Measure	550	556	breast
I-outcome-Measure	557	563	cancer
I-outcome-Measure	564	572	survival
O	573	576	and
B-outcome-Measure	577	582	local
I-outcome-Measure	583	590	control
I-outcome-Measure	591	593	of
I-outcome-Measure	594	597	the
I-outcome-Measure	598	605	disease
O	605	606	.

O	607	614	Between
O	615	619	1987
O	620	623	and
O	624	628	1992
O	628	629	,
B-control-participants	630	633	239
O	634	642	patients
O	643	647	were
O	648	656	assigned
O	657	659	to
O	660	667	surgery
O	668	672	plus
O	673	682	tamoxifen
O	683	686	and
B-intervention-participants	687	690	235
O	691	693	to
O	694	703	tamoxifen
O	704	709	alone
O	709	710	.

O	711	720	Treatment
O	721	725	arms
O	726	730	were
O	731	741	comparable
O	742	745	for
O	746	751	tumor
O	752	756	size
O	756	757	,
O	758	766	clinical
O	767	772	nodal
O	773	779	status
O	780	783	and
O	784	795	performance
O	796	802	status
O	802	803	.

O	804	806	At
O	807	808	a
O	809	815	median
O	816	822	follow
O	822	823	-
O	823	825	up
O	826	828	of
O	829	831	80
O	832	838	months
O	839	842	274
O	843	851	patients
O	852	855	had
B-outcome	856	860	died
O	860	861	.

O	862	864	No
O	865	875	difference
O	876	883	between
O	884	890	groups
O	891	894	had
O	895	902	emerged
O	903	905	in
B-outcome	906	913	overall
I-outcome	914	917	and
I-outcome	918	924	breast
I-outcome	925	931	cancer
I-outcome	932	940	survival
O	940	941	.

O	942	947	There
O	948	952	were
B-cv-bin-abs	953	955	27
B-outcome	956	961	local
I-outcome	962	974	progressions
O	975	977	in
O	978	981	the
O	982	989	surgery
O	990	994	plus
O	995	1004	tamoxifen
O	1005	1010	group
O	1011	1014	and
B-iv-bin-abs	1015	1018	106
O	1019	1021	in
O	1022	1025	the
O	1026	1035	tamoxifen
O	1035	1036	-
O	1036	1041	alone
O	1042	1047	group
O	1048	1049	(
O	1049	1050	P
O	1051	1052	=
O	1053	1054	0
O	1054	1055	.
O	1055	1059	0001
O	1059	1060	)
O	1060	1061	.

O	1062	1064	In
O	1065	1068	the
O	1069	1076	surgery
O	1077	1081	plus
O	1082	1091	tamoxifen
O	1092	1097	group
O	1097	1098	,
O	1099	1101	no
O	1102	1112	difference
O	1113	1115	in
B-outcome	1116	1123	overall
I-outcome	1124	1132	survival
O	1133	1136	had
O	1137	1144	emerged
O	1145	1154	according
O	1155	1157	to
O	1158	1161	the
O	1162	1171	extension
O	1172	1174	of
O	1175	1184	operation
O	1184	1185	.

O	1186	1189	The
O	1190	1194	long
O	1194	1195	-
O	1195	1199	term
O	1200	1207	results
O	1208	1210	of
O	1211	1214	the
O	1215	1220	study
O	1221	1228	confirm
O	1229	1232	the
O	1233	1234	3
O	1234	1235	-
O	1235	1239	year
O	1240	1247	interim
O	1248	1256	analysis
O	1257	1264	already
O	1265	1273	reported
O	1273	1274	.

O	1275	1282	Surgery
O	1283	1284	(
O	1284	1291	radical
O	1292	1294	or
O	1295	1302	minimal
O	1302	1303	)
O	1304	1312	followed
O	1313	1315	by
O	1316	1324	adjuvant
O	1325	1334	tamoxifen
O	1335	1339	does
O	1340	1343	not
O	1344	1350	modify
B-outcome	1351	1358	overall
I-outcome	1359	1362	and
I-outcome	1363	1369	breast
I-outcome	1370	1376	cancer
I-outcome	1377	1385	survival
O	1386	1388	as
O	1389	1397	compared
O	1398	1402	with
O	1403	1412	tamoxifen
O	1413	1418	alone
O	1419	1421	in
O	1422	1427	early
O	1428	1434	breast
O	1435	1441	cancer
O	1442	1444	of
O	1445	1450	older
O	1451	1456	women
O	1456	1457	.

O	1458	1465	Because
O	1466	1468	of
O	1469	1472	the
O	1473	1477	high
O	1478	1482	rate
O	1483	1485	of
O	1486	1491	local
O	1492	1504	progressions
O	1505	1509	with
O	1510	1519	tamoxifen
O	1520	1525	alone
O	1525	1526	,
O	1527	1534	minimal
O	1535	1542	surgery
O	1543	1551	followed
O	1552	1554	by
O	1555	1564	tamoxifen
O	1565	1572	appears
O	1573	1575	to
O	1576	1578	be
O	1579	1582	the
O	1583	1594	appropriate
O	1595	1604	treatment
O	1605	1607	in
O	1608	1612	such
O	1613	1621	patients
O	1621	1622	.

O	1623	1627	More
O	1628	1637	extensive
O	1638	1645	surgery
O	1646	1648	is
O	1649	1652	not
O	1653	1659	useful
O	1659	1660	.

O	1661	1670	Tamoxifen
O	1671	1676	alone
O	1677	1679	is
O	1680	1682	an
O	1683	1691	adequate
O	1692	1703	alternative
O	1704	1713	treatment
O	1714	1716	in
O	1717	1721	very
O	1722	1725	old
O	1726	1728	or
O	1729	1734	frail
O	1735	1743	patients
O	1743	1744	.
